Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy (Plasma-Target)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status: Active, not recruiting

Conditions: Cancer

Treatments: Drug: Immunotherapeutic Agent; Drug: Molecular Target

Study type: Interventional

Funder types: Other

Identifiers

NCT03835520

B403201836842 (Other Identifier)

2018/11JUI/248 (Registry Identifier)

UCL-ONCO 2018-02

Details and patient eligibility

About

The purpose of this study is to collect blood samples, as well as tumor tissue for genetic analysis. The collection of samples will allow the creation of a plasma bank. Targeted individuals are cancer patients of all types, treated with immunotherapy or targeted therapy.

Immunotherapy or targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.

With the aim to identify predictive markers of response to treatment or possible resistance mechanism, the plasma samples and the tumor samples will be used for genetic analysis, for example but not limited to, whole exome sequencing. This may lead to the discovery of some germinal mutations implicated in other diseases than cancer.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with cancer treated with one of the following regimens: Molecular targeted agents or Immunotherapy
• Paraffin-embedded tumor tissue available for immunohistochemistry and/or DNA extraction.
• Patient able to give written informed consent.

Exclusion criteria

• Patients with cancer treated with other regimen

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

MOLECULAR TARGETED THERAPIES

Experimental group

Description:

Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.

Treatment:

Drug: Molecular Target

IMMUNOTHERAPY

Experimental group

Description:

Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.

Treatment:

Drug: Immunotherapeutic Agent